iCAD Expands Executive Sales Leadership Team as Business Grows
18 Décembre 2023 - 2:00PM
iCAD, Inc. (NASDAQ: ICAD), a global medical technology leader in
innovative cancer-detection solutions, today announced the
expansion of its sales leadership with the addition of Peter
Graham, as Senior Vice President, North American Sales and a role
change for Bill Keyes to Senior Vice President, Global Sales
Operations, both effective immediately.
“Together, Bill and Peter bring proven expertise to drive
growth, increase revenue, and deliver results. As we expand iCAD’s
impact worldwide, introduce new solutions under the ProFound Breast
Health Suite portfolio, and launch programs with new partners,
experienced and seasoned sales leadership is critical to the
success of our organization,” said Michelle Strong, Chief
Operations Officer of iCAD.
Since joining iCAD in December of 2022, Bill Keyes has developed
and deployed sales processes and procedures to organize a more
streamlined sales operation and provide for a deeper view of iCAD’s
customers and areas for growth. In his new role, Keyes will
continue to provide sales operation guidance in North America and
beyond, while building partnerships and business strategies for
global growth.
Peter Graham is assuming responsibilities for revenue growth
across North America, bringing more than 20 years of experience in
the breast health, diagnostic, and medical solutions space
including roles at Tempus Labs, Arterys, Volpara and Xoft. Under
Peter’s leadership, iCAD will be adding sales staff to support its
growth. “We’re thrilled to welcome Peter to iCAD. His expertise in
women’s health solutions, knowledge of the market needs and
collaborative spirit are aligned with iCAD’s aim to bring
best-in-class artificial intelligence (AI) informed mammograms and
risk assessment solutions to women everywhere, helping create a
world where cancer can’t hide,” said Ms. Strong.
About iCAD, Inc. iCAD, Inc. (NASDAQ: ICAD)
is a global leader on a mission to create a world where
cancer can’t hide by providing clinically proven AI-powered
solutions that enable medical providers to accurately and
reliably detect cancer earlier and improve patient
outcomes. Headquartered in Nashua, N.H., iCAD’s
industry-leading ProFound Breast Health Suite provides
AI-powered mammography analysis for breast cancer detection,
density assessment and risk evaluation. The ProFound Breast
Health Suite is cleared by the U.S. Food & Drug
Administration (FDA) and has received CE mark and Health
Canada licensing. Used by thousands of providers serving
millions of patients, ProFound is available in over 50
countries. In the last five years alone, iCAD estimates reading
more than 40 million mammograms worldwide, with nearly 30% being
tomosynthesis. For more information,
visit www.icadmed.com.
iCAD Media Contacts: Media
Inquiries: pr@icadmed.com Investor
Inquiries: ir@icadmed.com
Icad (NASDAQ:ICAD)
Graphique Historique de l'Action
De Avr 2024 à Mai 2024
Icad (NASDAQ:ICAD)
Graphique Historique de l'Action
De Mai 2023 à Mai 2024